Hyoscyamine Sulfate


Bryant Ranch Prepack
Human Prescription Drug
NDC 63629-1028
Hyoscyamine Sulfate is a human prescription drug labeled by 'Bryant Ranch Prepack'. National Drug Code (NDC) number for Hyoscyamine Sulfate is 63629-1028. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Hyoscyamine Sulfate drug includes Hyoscyamine Sulfate - .125 mg/1 . The currest status of Hyoscyamine Sulfate drug is Active.

Drug Information:

Drug NDC: 63629-1028
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Hyoscyamine Sulfate
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Hyoscyamine Sulfate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Bryant Ranch Prepack
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:HYOSCYAMINE SULFATE - .125 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Oct, 2018
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 19 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2024
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Bryant Ranch Prepack
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1047905
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
UNII:F2R8V82B84
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
63629-1028-1100 TABLET in 1 BOTTLE (63629-1028-1)08 Mar, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Hyoscyamine sulfate hyoscyamine sulfate hyoscyamine sulfate hyoscyamine starch, corn lactose monohydrate magnesium stearate mannitol stearic acid fd&c blue no. 1 n;104 structure

Drug Interactions:

Drug interactions: additive adverse effects resulting from cholinergic blockade may occur when hyoscyamine sulfate is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (mao) inhibitors, tricyclic antidepressants or some antihistamines. antacids may interfere with the absorption of hyoscyamine sulfate. administer hyoscyamine sulfate before meals; antacids after meals.

Indications and Usage:

Indications and usage hyoscyamine sulfate tablets, usp are effective as adjunctive therapy in the treatment of peptic ulcer. they can also be used to control gastric secretions, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm and associated abdominal cramps. may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis and acute enterocolitis. for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). hyoscyamine sulfate tablets, usp are indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a “drying agent” in the relief of symptoms of acute rhinitis; in th
e therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. may be used in the therapy of poisoning by anticholinesterase agents.

Warnings:

Warnings in the presence of high environmental temperature, heat prostration can occur with drug use (fever and heat stroke due to decreased sweating). diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. in this instance, treatment with this drug would be inappropriate and possibly harmful. like other anticholinergic agents, hyoscyamine sulfate may produce drowsiness, dizziness or blurred vision. in this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug. psychosis has been reported in sensitive individuals given anticholinergic drugs including hyoscyamine sulfate. cns signs and symptoms include confusion, disorientation, short-term memory loss, hallucinations, dysarthria, ataxia, coma, euphoria, anxiety, decreased anxiety, fatigue, insomnia, agitation and mannerisms and in
appropriate affect. these cns signs and symptoms usually resolve within 12 to 48 hours after discontinuation of the drug.

General Precautions:

General: use with caution in patients with: autonomic neuropathy, hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, hypertension and renal disease. investigate any tachycardia before giving any anticholinergic drugs since they may increase the heart rate. use with caution in patients with hiatal hernia associated with reflux esophagitis.

Dosage and Administration:

Dosage and administration dosage may be adjusted according to the conditions and severity of symptoms. adults and pediatric patients 12 years of age and older: 1 to 2 tablets every four hours or as needed. do not exceed 12 tablets in 24 hours. pediatric patients 2 to under 12 years of age: 1/2 to 1 tablet every four hours or as needed. do not exceed 6 tablets in 24 hours.

Contraindications:

Contraindications glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis); paralytic ileus, intestinal atony of elderly or debilitated patients; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.

Adverse Reactions:

Adverse reactions the following adverse reactions have been reported for hyoscyamine sulfate and for pharmacologically similar drugs with anticholinergic/antispasmodic action. adverse reactions may include dryness of the mouth; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; mydriasis; cycloplegia; increased ocular tension; loss of taste; headache; nervousness; drowsiness; weakness; fatigue; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; abdominal pain; diarrhea; allergic reactions or drug idiosyncrasies; urticaria and other dermal manifestations; ataxia; speech disturbance; some degree of mental confusion and/or excitement (especially in elderly persons); short-term memory loss; hallucinations; and decreased sweating. to report suspected adverse reactions, contact noble pharmaceuticals, llc at 1-888-514-4727 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Drug Interactions:

Drug interactions: additive adverse effects resulting from cholinergic blockade may occur when hyoscyamine sulfate is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (mao) inhibitors, tricyclic antidepressants or some antihistamines. antacids may interfere with the absorption of hyoscyamine sulfate. administer hyoscyamine sulfate before meals; antacids after meals.

Geriatric Use:

Geriatric use: reported clinical experience has not identified differences in safety between patients aged 65 and over and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Overdosage:

Overdosage the signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dryness of the mouth, difficulty in swallowing and cns stimulation. measures to be taken are immediate lavage of the stomach and injection of physostigmine 0.5 to 2 mg intravenously and repeated as necessary up to a total of 5 mg. fever may be treated symptomatically (tepid water sponge baths, hypothermic blanket). excitement to a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100-200 ml of a 2% solution) by rectal infusion. in the event of progression of the curare-like effect to paralysis of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns. in rats, the ld50 for hyoscyamine is 375 mg/kg. hyoscyamine sulfate is dialyzable.

Description:

Description hyoscyamine sulfate tablets, usp contain 0.125 mg hyoscyamine sulfate formulated for oral administration. hyoscyamine sulfate is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. the empirical formula is (c 17 h 23 no 3 ) 2 •h 2 so 4 •2h 2 o and the molecular weight is 712.85. chemically, it is benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1] oct-3-yl ester, [3(s)-endo]-, sulfate (2:1), dihydrate with the following structure: each tablet also contains as inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, mannitol, stearic acid, and fd&c blue #1.

Clinical Pharmacology:

Clinical pharmacology hyoscyamine sulfate inhibits specifically the actions of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. these peripheral cholinergic receptors are present in the autonomic effector cells of the smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node and the exocrine glands. at therapeutic doses, it is completely devoid of any action on the autonomic ganglia. hyoscyamine sulfate inhibits gastrointestinal propulsive motility and decreases gastric acid secretion. hyoscyamine sulfate also controls excessive pharyngeal, tracheal and bronchial secretions. hyoscyamine sulfate is absorbed totally and completely by oral administration. once absorbed, hyoscyamine sulfate disappears rapidly from the blood and is distributed throughout the entire body. the half-life of hyoscyamine sulfate is 2 to 3 1/2 hours. hyoscyamine sulfate is partly hy
drolyzed to tropic acid and tropine but the majority of the drug is excreted in the urine unchanged within the first 12 hours. only traces of this drug are found in breast milk. hyoscyamine sulfate passes the blood brain barrier and the placental barrier.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility: no long-term studies in animals have been performed to determine the carcinogenic, mutagenic or impairment of fertility potential of hyoscyamine sulfate; however, 40 years of marketing experience with hyoscyamine sulfate shows no demonstrable evidence of a problem.

How Supplied:

How supplied hyoscyamine sulfate tablets, usp, 0.125 mg are light blue, round, biconvex tablets, debossed with “n” on one side and “104” on the other. bottles of 100 ndc 63629-1028-1 store at controlled room temperature 20c°-25°c (68f°-77°f); excursion permitted to 15c°-30°c (59f°-86°f) see usp controlled room temperature. dispense in tight, light-resistant containers as defined in usp/nf with a child-resistant closure. keep this and all drugs out of the reach of children.

Information for Patients:

Information for patients: like other anticholinergic agents, hyoscyamine sulfate may produce drowsiness, dizziness or blurred vision. in this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug. use of hyoscyamine sulfate may decrease sweating resulting in heat prostration, fever or heat stroke; febrile patients or those who may be exposed to elevated environmental temperatures should use caution.

Package Label Principal Display Panel:

Hyoscyamine sulfate 0.125mg tablet #100 label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.